Back to Journals » ClinicoEconomics and Outcomes Research » Volume 7
Original Research
![Noteworthy comment: In health technology assessment (HTA) agencies where cost-effectiveness plays a role in decision-making, an incremental cost-effectiveness ratio (ICER) threshold is often used to inform reimbursement decisions. Acceptance of submissions with higher-than-threshold ICERs varied by HTA agency and was not significantly influenced by disease category. Such submissions must be accompanied by robust, concrete, and transparent evidence in order to achieve patient access.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Acceptance of health technology assessment submissions with incremental cost-effectiveness ratios above the cost-effectiveness threshold
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
20,096 | Dovepress* | 17,237+ | 1,771 | 19,008 | |
PubMed Central* | 2,859 | 752 | 3,611 | ||
Totals | 20,096 | 2,523 | 22,619 | ||
*Since 31 August 2015 +Since July 2016 |
Total mentioned | Delicious | Others | |||
---|---|---|---|---|---|
2 | 0 | 0 | 0 | 1 | 1 |
View citations on PubMed Central and Google Scholar